Results of Global Phase III Study with Chugai's HEMLIBRA® for Hemophilia A Without Inhibitors Published in the New England Journal of Medicine
Pharmaceutical Co., Ltd.
(TOKYO:4519) today announced that results
of the HAVEN 3 study (NCT02847637), the global phase III study
evaluating hemophilia A treatment, HEMLIBRA®
emicizumab [genetical recombination]), were published in the 30 August
2018 issue of the New England Journal of Medicine (NEJM).
Quick video summary by NEJM: https://www.nejm.org/do/10.1056/NEJMdo005333/full/
The study evaluated the efficacy and safety of HEMLIBRA subcutaneous injection, once a week and once every two weeks, in people with hemophilia A (12 years of age or older) without inhibitors to factor VIII. Detailed results of the study were presented at the World Federation of Hemophilia (WFH) 2018 World Congress held in Glasgow, Scotland on May 21, 2018.
“This is the third time that the clinical data of HEMLIBRA have been published in NEJM, following the results of the phase I/II studies and the first phase III study. It demonstrates a high medical value that the drug may bring to the treatment of hemophilia A,” said Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit, Dr. Yasushi Ito. “We are committed to deliver HEMLIBRA which has been created with our proprietary bispecific antibody technologies, as a new treatment option to people with hemophilia A without inhibitors as early as possible in cooperation with Roche.”
In May 2018, HEMLIBRA was launched in Japan for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with congenital factor VIII deficiency (hemophilia A) with factor VIII inhibitors. An application for an additional indication of the treatment of hemophilia A without factor VIII inhibitors has been filed in April in Japan. Applications for the same additional indication have also been filed in the United States and Europe. In the U.S., the Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation in April, and Priority Review in June, for this line extension. In Europe, the review by the EU Committee for Medicinal Products for Human Use (CHMP) is ongoing.
Chugai Presents Results of Two Pivotal Phase III Studies for its
Bispecific Antibody HEMLIBRA at WFH 2018 (Press release issued on May
Chugai Pharmaceutical is one of Japan’s leading research-based
pharmaceutical companies with strengths in biotechnology products.
Chugai, based in Tokyo, specializes in prescription pharmaceuticals and
is listed on the 1st section of the Tokyo Stock Exchange. As an
important member of the Roche Group, Chugai is actively involved in R&D
activities in Japan and abroad. Specifically, Chugai is working to
develop innovative products which may satisfy the unmet medical needs,
mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
The consolidated revenue in 2017 of Chugai totalled 534.2 billion yen and the operating income was 103.2 billion yen (IFRS Core basis).
Additional information is available on the internet at https://www.chugai-pharm.co.jp/english .
Trademarks used or mentioned in this release are protected by law.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
CA-ARENSIS/SCHNEIDER25.9.2018 15:02 | pressemeddelelse
Arensis and Schneider Electric Launch Smart Microgrid Partnership and Development of ENTRADE IO Blockchain Technology
RI-CLARKE-VALVE25.9.2018 15:02 | pressemeddelelse
Clarke Valve Closes $5.5 Million Venture Funding Round Led by OGCI Climate Investments
CA-ANALOGIX25.9.2018 15:02 | pressemeddelelse
Analogix Introduces Industry’s Lowest Power eDP TCON with In-Cell Touch for Latest Generation Notebooks
MA-TAKEDA-PHARMACEUTICAL25.9.2018 14:34 | pressemeddelelse
Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial Showing a Reduction in Risk of Disease Progression or Death of More Than 50 Percent Versus Crizotinib in First-Line Advanced ALK+ NSCLC
SOFTOMOTIVE25.9.2018 14:17 | pressemeddelelse
Softomotive and Enate Partner to Help Clients Orchestrate Workflows across Their RPA Ecosystem
CA-SCIENTIST.COM25.9.2018 14:08 | pressemeddelelse
Scientist.com Adds Experienced Drug Hunter Mark Herbert to Management Team
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum